Category: Parkinson's Disease (Other)
Objective: To assess the safety and efficacy of a personalized burst patterned STN-DBS (bDBS) vs. conventional high-frequency DBS (cDBS).
Background: A physiological rationale suggests possible advantages of bDBS over cDBS, but clinical evidence is lacking.
Method: RESET-DBS (clinicaltrials.gov NCT07340073) was a reprogramming study in PD patients implanted with a Boston Scientific Vercise Genus RC DBS system. Eligible candidates had clinically optimized cDBS for at least 3 months. The Chronos Software was used to deliver a predefined set of burst patterns to the exact same neural activation volume as cDBS.
During a programming visit we assessed acute responses to repeated periods of bDBS varying in burst duration (BD), interburst duration (IBD) or random combinations, keeping intraburst frequency, amplitude and pulse width identical to cDBS. Up to three personalized bDBS settings were identified, which were sufficiently effective and tolerable to transition to a 4-week blinded at home comparison to cDBS. Participants were instructed to keep medication constant, change the programs with their controller according to protocol and determine their preferred setting. Telephone visits ensured patient safety and protocol compliance. The primary outcome was the patient preference of bDBS vs. cDBS. Exploratory outcomes included the change in MDS-UPDRS I-IV, PDQ-39 and videokinematic parameters between the baseline and closeout visits.
Results: After completing the blinded and randomized 4-week period, 5/10 patients preferred one of the bDBS programs over cDBS. bDBS preference was associated with equivalent motor outcome on MDS-UPDRS III, but significantly greater ADL and QoL improvements compared to baseline. This group difference was explained by a higher baseline impairment of bDBS responders in ADL and QoL.
Conclusion: bDBS is feasible during a 4-week real-world assessment, provides equivalent motor benefit to cDBS and may have clinical advantages in a subgroup of PD patients with inferior ADL and QoL outcomes with cDBS. The clinical motor and non-motor response profile of chronic bDBS should be characterized in a larger study.
To cite this abstract in AMA style:
F. Lange, L. Juarez Paz, P. Köberle, B. Duarte, G. Adacay, T. Sil, M. Reich, A. Kühn, M. Muthuraman, H. Bokil, J. Volkmann. RESET-DBS: An exploratory study on the safety and efficacy of personalized burst-patterned deep brain stimulation (DBS) in Parkinson’s Disease (PD) [abstract]. Mov Disord. 2026; 41 (suppl 1). https://www.mdsabstracts.org/abstract/reset-dbs-an-exploratory-study-on-the-safety-and-efficacy-of-personalized-burst-patterned-deep-brain-stimulation-dbs-in-parkinsons-disease-pd/. Accessed October 1, 2026.« Back to 2026 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/reset-dbs-an-exploratory-study-on-the-safety-and-efficacy-of-personalized-burst-patterned-deep-brain-stimulation-dbs-in-parkinsons-disease-pd/